Individualized MVA-based vaccine TG4050

{
  "id": "MLC-T-ONC-014440",
  "term": "Individualized MVA-based vaccine TG4050",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.",
  "synonyms": [
    "MVA-neoantigen vaccine TG4050",
    "neoantigen-expressing MVA-based vaccine TG4050",
    "TG4050 vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/individualized-mva-based-vaccine-tg4050/"
}